1. ARGO: A RANDOMISED PHASE II STUDY OF ATEZOLIZUMAB WITH RITUXIMAB, GEMCITABINE AND OXALIPLATIN IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA WHO ARE NOT CANDIDATES FOR HIGH‐DOSE THERAPY. (12th June 2019) Authors: Davies, A.J.; Tansley Hancock, O.; Cummin, T.; Caddy, J.; Stanton, L.; Burton, C.; Barrans, S.; Coleman, A.; Osborne, W.; McKay, P.; Griffiths, G.; Johnson, P. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 555 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. LONGITUDINAL ANALYSES OF DIAGNOSTIC‐RELAPSE BIOPSIES OF DIFFUSE LARGE B CELL LYMPHOMA SUGGEST THAT RELAPSE IS MEDIATED BY DISTINCT MECHANISMS IN ABC AND GCB LYMPHOMA. (12th June 2019) Authors: Korfi, K.; Araf, S.; Bewicke‐Copley, F.; Kumar, E.; Cummin, T.; Ashton‐Key, M.; Barrans, S.; Van Hoppe, S.; Burton, C.; Elshiekh, M.; Rule, S.; Crosbie, N.; Clear, A.; Calaminici, M.; Menon, G.; Sha, C.; Bentley, M.; Nagano, A.; Davies, A.; Painter, D. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 142 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗